ArticleEClinicalMedicine2021
Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases.
Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The occurrence of thromboembolism among patients with coronavirus disease 2019: A systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Minimum Data Set and Metadata for Active Vaccine Safety Surveillance: Systematic Review.JMIR public health and surveillance · 2025Pooled it
- Cumulative Evidence for the Association of Thrombosis and the Prognosis of COVID-19: Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review.Journal of primary care & community healthPooled it
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.The New England journal of medicine · 2021Trial
- Xenosialylation as immunological chimerism: a host-centered unifying model for viral and post-vaccination immune complications.European cytokine network · 2026Review
- Subdural and epidural hematoma following lumbar puncture in patients on anticoagulants or antiplatelets: A retrospective propensity score-matched registry study.Acta neurologica Belgica · 2026Article
- A deep learning based radiomics model for differentiating intraparenchymal hematoma induced by cerebral venous thrombosis.Scientific reports · 2025Article
- Etiology and Risk Factors for Splanchnic Vein Thrombosis in Non-Cirrhotic, Non-Neoplastic Patients: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Effects of early propranolol administration on mortality from severe, traumatic brain injury: a retrospective propensity score-matched registry study.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025Article
- COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.AIMS neuroscience · 2025Review
- Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality.Neurocritical care · 2024Article
- Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study.NPJ vaccines · 2024Article
- Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19.NPJ vaccines · 2024Article
- Characteristics and outcomes of cerebral venous thrombosis associated with COVID-19.European stroke journal · 2024Article
- Thrombotic Long-Term Consequences of SARS-CoV-2 Infection in Patients with Compensated Cirrhosis: A Propensity Score-Matched Analysis of a U.S. Database.Diseases (Basel, Switzerland) · 2024Article
- Risk of Blood Clots After COVID-19 Vaccination and Infection: A Risk-Benefit Analysis.Research square · 2024Article
- Article
- Article
- Macular perfusion changes in people administered two types of COVID-19 vaccines: optical coherence tomography angiography study.Arquivos brasileiros de oftalmologia · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are concerns about a link between the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines against COVID-19 and cerebral venous thrombosis (CVT) and other thrombotic events. One key missing component of the risk-benefit analysis of using such vaccines is the risk of these severe thrombotic events following COVID-19.
methodsUsing a retrospective cohort study based on electronic health records primarily in the USA, the absolute risks of CVT and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19 (made between January 20, 2020 and March 25, 2021) were calculated. The risks were compared to cohorts of patients with influenza (diagnosed within the same period) and people receiving an mRNA vaccine (i.e. not the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines) against COVID-19 (matched for demographics and the main risk factors for CVT and PVT).
findingsA total of 537,913 patients with a COVID-19 diagnosis were included. The incidence of CVT in the two weeks after a COVID-19 diagnosis was 42.8 per million people (95% CI 28.5-64.2). This was significantly higher than in a matched cohort of people who received an mRNA vaccine (RR = 6.33, 95% CI 1.87-21.40,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.